SAR348830 is primarily investigated for its potential therapeutic applications in the field of oncology. It is being studied as a selective inhibitor of specific kinases involved in cancer cell proliferation and survival. Researchers are exploring its efficacy in targeting certain types of cancers, particularly those driven by specific genetic mutations or signaling pathways. Preclinical studies suggest it may help in inhibiting tumor growth and improving outcomes in combination with other cancer therapies. Its application is focused on advancing personalized medicine approaches, aiming to provide targeted treatment options for patients with limited therapeutic alternatives. Ongoing clinical trials are assessing its safety, tolerability, and effectiveness in human subjects.